Involvement of Chemokine Receptor 4/Stromal Cell–Derived Factor 1 System during Osteosarcoma Tumor Progression
- Eliana Perissinotto1,
- Giuliana Cavalloni1,
- Francesco Leone1,
- Valentina Fonsato1,
- Stefania Mitola2,
- Giovanni Grignani1,
- Nadia Surrenti1,
- Dario Sangiolo1,
- Federico Bussolino2,
- Wanda Piacibello1 and
- Massimo Aglietta1
- Department of Oncological Sciences and Laboratories of 1Clinical Oncology and 2Molecular Angiogenesis, University of Turin Medical School, IRCC Institute for Cancer Research and Treatment, Turin, Italy
- Requests for reprints:
Giuliana Cavalloni, Department of Oncological Sciences, Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo, Turih, Italy. Phone: 39-011-9933523; Fax: 39-011-9933524; E-mail: giuliana.cavalloni{at}ircc.it.
Abstract
Despite intensive chemotherapy and surgery treatment, lung and bone metastasis develop in about 30% of patients with osteosarcoma. Mechanisms for this preferential metastatic behavior are largely unknown. We investigated the role of the chemokine receptor 4 (CXCR4)/stromal cell–derived factor 1 (SDF-1) system to drive the homing of osteosarcoma cells. We analyzed the expression of the CXCR4 and SDF-1 proteins on several osteosarcoma cell lines and the effects of SDF-1 on migration, adhesion, and proliferation of these cancer cells. In vitro assays showed that the migration of osteosarcoma cells expressing CXCR4 receptor follows an SDF-1 gradient and that their adhesion to endothelial and bone marrow stromal cells is promoted by SDF-1 treatment. Moreover, the production of matrix metalloproteinase-9 is increased after SDF-1 exposure. We finally proved in a mouse model our hypothesis of the CXCR4/SDF-1 axis involvement in the metastatic process of osteosarcoma cells. Development of lung metastasis after injection of osteosarcoma cells was prevented by the administration of a CXCR4 inhibitor, the T134 peptide. These data show a possible explanation for the preferential osteosarcoma metastatic development into the lung, where SDF-1 concentration is high, and suggest that molecular strategies aimed at inhibiting the CXCR4/SDF-1 pathway, such as small-molecule inhibitors or anti-CXCR4 antibodies, might prevent the dissemination of osteosarcoma cells.
Footnotes
-
Grant support: Associazione Italiana per la Ricerca sul Cancro, Milan, Italy, Consiglio Nazionale delle Ricerche Progetto Strategico Oncologia, Associazione Donatrici Italiane Cordone Ombelicale (E. Perissinotto), Ministero dell'Istruzione, dell'Università e della Ricerca, Ricerca finalizzata 2001, sottoprogetto B55.4.2 (G. Cavalloni, S. Mitola, D. Sangiolo, W. Piacibello, and M. Aglietta), and Compagnia di San Paolo (F. Leone).
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted October 29, 2004.
- Received March 23, 2004.
- Revision received October 6, 2004.










